![John Maher](/newimages/folsm/person-profile/scps/john-maher.xc4ee9fce.png?f=webp)
Dr John Maher
Consultant and Senior Lecturer in Immunology
Research interests
- Cancer
- Immunology
Contact details
Biography
Dr John Maher is a Senior Lecturer within the Comprehensive Cancer Centre.
Research
![car mechanics RG thumbnail](/newimages/folsm/hero-banner/scps/car-mechanics-rg-thumbnail.x51fbea40.png?width=380&height=215&fit=crop&f=webp)
CAR Mechanics Group
The CAR Mechanics Group originated in 2004 and has sought to develop and translate novel CAR T-cell strategies for the treatment of patients with refractory solid tumours. We have developed several experimental CAR approaches in addition to ancillary technologies that enable improved CAR T-cell expansion and homing to sites of disease. The CAR Mechanics group has advanced one candidate named T4 immunotherapy to Phase 1 clinical trial evaluation with funding from the Jon Moulton Charitable Foundation, Wellcome Trust and the Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust.
![experimental-oncology](/newimages/researchproject/thumb-2021/experimental-oncology.x24bb812f.jpg?crop=780,440,0,0&width=380&height=215&fit=crop&f=webp)
Experimental Oncology
The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.
Project status: Ongoing
![Immunology and Immunotherapy Programme Header](/newimages/thumbnails/Immunology-seminar-series.xa626835f.jpg?w=906&h=440&crop=780,440,0,0&width=380&height=215&fit=crop&f=webp)
Cancer Immunology & Immunotherapy
Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.
Project status: Ongoing
News
Leucid Bio gains clinical trial approval for new CAR-T Cell Therapy
The King’s spin-out will dose its first patients by the end of 2023 in order to test its new CAR-T Cell Therapy, designed for the treatment of adults with...
![clinical trials](/newimages/ioppn/research-and-development/clinical-trials.x15078c7a.jpg?w=780&h=520&crop=780,440,0,40&f=webp)
New papers give fresh promise for CAR T-cell cancer immunotherapy
The two studies, published in Cell Reports Medicine and Froniters in Immunology, have provided new insights into a specific type of CAR T-cell immunotherapy...
![cancer cell cytotoxic T-cells 780x450](/newimages/folsm/cancer-cell-cytotoxic-t-cells-780x450.x094659a1.png?crop=780,440,0,5&f=webp)
CAR-T therapy modifications provides new promise for cancer immunotherapies
Researchers from King’s and Leucid Bio have made additional modifications to CAR T-cells receptors, in collaboration with LUMICKS, improving its therapeutic...
![T cell therapies cancer cell 780x450](/newimages/folsm/t-cell-therapies-cancer-cell-780x450.x252327bd.png?crop=780,440,0,5&f=webp)
King's spin out Leucid Bio wins funding boost for CAR-T therapies
Researchers developing pioneering cell therapies for hard-to-treat cancers have received a significant funding boost.
![Cancer cells](/newimages/folsm/main-article/scps/cancer-cells.x489f12c2.png?crop=780,440,0,5&f=webp)
Engineering T-cells to selectively target cancer
Researchers from the Faculty of Life Sciences & Medicine have re-designed the genetic code of cells which can be trained to aggressively attack solid...
![Researchers Drs James Arnold (Left), Paris Kosti (Middle) and John Maher (right) who developed HypoxiCAR.](/newimages/folsm/main-article/scps/news/Engineering-T-cells-to-selectively-target-cancerous-tumours.xce438237.png?f=webp)
Events
![Correct DNA (3)780x450](/newimages/folsm/main-article/bmb/correct-dna-3780x450.x0efc66d0.png?crop=780,440,0,5&f=webp)
CAR T-cell immunotherapy of solid tumours – learning from the clinic and lab in parallel
Speaker: John Maher, Division of Cancer Studies, King's College London
Please note: this event has passed.
Features
Transforming cancer care at King's
King’s is the site of future breakthroughs, transforming cancer care and therapies through innovative research. An injection of philanthropic donations...
![cancer-cells-blue](/newimages/folsm/hero-banner/scps/cancer-cells-blue.xac798747.png?f=webp)
Spotlight
How King's continues to tackle cancer and support cancer care and research
Saturday 4 February marks World Cancer Day. In order to honour this key date, we have highlighted some of the most important cancer-themed stories that have...
![Cancer cells](/image-library/Press-Photos/Cancer-cells.x41008e73.jpg?w=1920&h=1080&f=webp)
Research
![car mechanics RG thumbnail](/newimages/folsm/hero-banner/scps/car-mechanics-rg-thumbnail.x51fbea40.png?width=380&height=215&fit=crop&f=webp)
CAR Mechanics Group
The CAR Mechanics Group originated in 2004 and has sought to develop and translate novel CAR T-cell strategies for the treatment of patients with refractory solid tumours. We have developed several experimental CAR approaches in addition to ancillary technologies that enable improved CAR T-cell expansion and homing to sites of disease. The CAR Mechanics group has advanced one candidate named T4 immunotherapy to Phase 1 clinical trial evaluation with funding from the Jon Moulton Charitable Foundation, Wellcome Trust and the Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust.
![experimental-oncology](/newimages/researchproject/thumb-2021/experimental-oncology.x24bb812f.jpg?crop=780,440,0,0&width=380&height=215&fit=crop&f=webp)
Experimental Oncology
The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.
Project status: Ongoing
![Immunology and Immunotherapy Programme Header](/newimages/thumbnails/Immunology-seminar-series.xa626835f.jpg?w=906&h=440&crop=780,440,0,0&width=380&height=215&fit=crop&f=webp)
Cancer Immunology & Immunotherapy
Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.
Project status: Ongoing
News
Leucid Bio gains clinical trial approval for new CAR-T Cell Therapy
The King’s spin-out will dose its first patients by the end of 2023 in order to test its new CAR-T Cell Therapy, designed for the treatment of adults with...
![clinical trials](/newimages/ioppn/research-and-development/clinical-trials.x15078c7a.jpg?w=780&h=520&crop=780,440,0,40&f=webp)
New papers give fresh promise for CAR T-cell cancer immunotherapy
The two studies, published in Cell Reports Medicine and Froniters in Immunology, have provided new insights into a specific type of CAR T-cell immunotherapy...
![cancer cell cytotoxic T-cells 780x450](/newimages/folsm/cancer-cell-cytotoxic-t-cells-780x450.x094659a1.png?crop=780,440,0,5&f=webp)
CAR-T therapy modifications provides new promise for cancer immunotherapies
Researchers from King’s and Leucid Bio have made additional modifications to CAR T-cells receptors, in collaboration with LUMICKS, improving its therapeutic...
![T cell therapies cancer cell 780x450](/newimages/folsm/t-cell-therapies-cancer-cell-780x450.x252327bd.png?crop=780,440,0,5&f=webp)
King's spin out Leucid Bio wins funding boost for CAR-T therapies
Researchers developing pioneering cell therapies for hard-to-treat cancers have received a significant funding boost.
![Cancer cells](/newimages/folsm/main-article/scps/cancer-cells.x489f12c2.png?crop=780,440,0,5&f=webp)
Engineering T-cells to selectively target cancer
Researchers from the Faculty of Life Sciences & Medicine have re-designed the genetic code of cells which can be trained to aggressively attack solid...
![Researchers Drs James Arnold (Left), Paris Kosti (Middle) and John Maher (right) who developed HypoxiCAR.](/newimages/folsm/main-article/scps/news/Engineering-T-cells-to-selectively-target-cancerous-tumours.xce438237.png?f=webp)
Events
![Correct DNA (3)780x450](/newimages/folsm/main-article/bmb/correct-dna-3780x450.x0efc66d0.png?crop=780,440,0,5&f=webp)
CAR T-cell immunotherapy of solid tumours – learning from the clinic and lab in parallel
Speaker: John Maher, Division of Cancer Studies, King's College London
Please note: this event has passed.
Features
Transforming cancer care at King's
King’s is the site of future breakthroughs, transforming cancer care and therapies through innovative research. An injection of philanthropic donations...
![cancer-cells-blue](/newimages/folsm/hero-banner/scps/cancer-cells-blue.xac798747.png?f=webp)
Spotlight
How King's continues to tackle cancer and support cancer care and research
Saturday 4 February marks World Cancer Day. In order to honour this key date, we have highlighted some of the most important cancer-themed stories that have...
![Cancer cells](/image-library/Press-Photos/Cancer-cells.x41008e73.jpg?w=1920&h=1080&f=webp)